José Barbosa Mello

Novonor engages in infrastructure and energy solutions. Its services include engineering and construction, industry, development and operation of infrastructure and energy projects, creating integrated and innovative solutions that serve both its clients and its communities. The company was founded in 1981and is headquartered in Salvador, Brazil.

Odbinv SA operates a holding company with interest in engineering, construction, and chemical and petrochemical activities. The company was founded on August 12, 1966 and is headquartered in Salvador, Brazil.

Part of Opthea Ltd., Vegenics Pty Ltd. is an Australian company that provides medical research, development, and commercialization of biologic drugs. Vegenics was acquired by Opthea Ltd. on August 14, 2008 for $5.06 million.

Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY.

Ocyan Participações SA engages in the provision of oil and gas exploration, drilling, and extraction services. Its services include offshore drilling, pipe laying services, installment and manufacturing of subsea equipment, and offshore maintenance and services. The company was founded on November 7, 2006 and is headquartered in Rio de Janeiro, Brazil.

Part of Cancer Research Institute, Cancer Vaccine Acceleration Co. LLC is an alternative investment manager. The company is based in New York, NY.

Fundação Odebrecht focuses on the youth and family development in order to create solutions together with local communities, based on their capabilities and needs. The company was founded by Norberto Odebrecht in 1965 and is headquartered in Salvador, Brazil.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

Biozeus Biopharmaceutical SA operates as a drug development company. It engages in the identifying early-stage drug candidates from Brazilian research institutions and develop them into new therapies for improving and saving lives, worldwide. The company is headquartered in Rio de Janeiro, Brazil.

iOX Therapeutics Ltd. provides cancer therapeutics services. The company was founded by Vincenzo Cerundolo in February 2015 and is headquartered in London, the United Kingdom.